Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients

Fan, Jinping; Yu, Haiying; Lv, Ying; Yin, Liguo

doi:10.1007/s13277-015-3994-x

Cited by 23 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a small protein playing pivotal roles in redox homeostasis and cell survival, and it is usually highly expressed in many cancers [101]: indeed, in response to reactive oxygen species (ROS) associated to the tumors, thioredoxin and DJ-1 are upregulated to limit or reverse cell damages [102,103]. In our samples we found two close isoforms of thioredoxin increased respectively of 3.7 and 2.5 folds in tumors.…”

Section: Thioredoxin Thio (Txn)mentioning

confidence: 53%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Pucci‐Minafra¹,

Cara²,

Musso³

et al. 2017

Preprint

View full text Add to dashboard Cite

Abstract:The present investigation has been conducted on one hundred tissue fragments of breast cancer, collected and immediately cryopreserved following the surgical resection. The fragments were selected from patients with invasive ductal carcinoma of the breast, the most common and potentially aggressive type of mammary cancer, with the objective to increase the knowledge of breast cancer molecular markers, useful for diagnostic and prognostic categorization of patients, in assessing postsurgical therapeutic regimes. The proteomic screening, by 2D-IPG and mass spectrometry, allowed us to identify two main classes of protein clusters: proteins expressed ubiquitously at high levels in all patients, and proteins expressed sporadically among the same patients. Within the group of ubiquitous proteins, glycolytic enzymes and proteins with anti-apoptotic activity were predominant. Among the sporadic ones, proteins involved in cell motility, molecular chaperones and proteins involved in the detoxification appeared prevalent. The data of the present study indicates that the primary tumor growth is generally supported by two concurrent pathways: the inhibition of apoptosis and the stimulation of cellular proliferation. The second phase of the evolution of the tumor can be prematurely scheduled by the occasional presence of proteins involved in cell motility and in the defenses of the oxidative stress. To our knowledge this report on large-scales proteomics of breast cancer is currently a unique approach in the literature that offers the opportunity to evaluate the presence and recurrence of proteins to be used as prognostic indicators and susceptibility to metastasis in patients operated on for invasive ductal carcinoma of the breast.

show abstract

Section: Thioredoxin Thio (Txn)mentioning

confidence: 53%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Pucci‐Minafra¹,

Cara²,

Musso³

et al. 2017

Preprint

View full text Add to dashboard Cite

show abstract

“…Of the 11 proteins that were added to CA125 in the multi-protein classifier, eight of the proteins (CD40.L, CD69, CXCL9, EGFR, EpCAM, SELE, TF, and VEGFR2) have been associated with ovarian cancer in previous studies [ 29 , 79 – 84 ]; however, CXCL9 has only been examined in ovarian cancer tissues [ 85 ], and CD69 was associated with T-lymphocytes in ovarian cancer ascites fluid [ 86 ]. The remaining three proteins (CXCL13, PARK7, and LAP.TGF-β1) do not appear in the literature as having an association with ovarian cancer, however they have been identified in other types of cancer [ 69 – 71 , 87 , 88 ]. Interestingly, 6 of the 11 proteins that were added to CA125 in the multi-protein classifier were lower in ovarian cancer sera relative to the healthy controls, suggesting that future biomarker discovery studies should not exclusively focus on proteins that have increased levels in ovarian cancer serum.…”

Section: Discussionmentioning

confidence: 99%

A multiplex platform for the identification of ovarian cancer biomarkers

et al. 2017

View full text Add to dashboard Cite

BackgroundCurrently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. MethodsWe used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek® Multiplex Oncology Plates) can simultaneously measure the expression of 92 proteins in serum based on a proximity extension assay. We analyzed serum samples from 81 women representing healthy, benign pathology, early, and advanced stage serous ovarian cancer patients. ResultsPrinciple component analysis and unsupervised hierarchical clustering separated patients into cancer versus non-cancer subgroups. Data from the Proseek® plate for CA125 levels exhibited a strong correlation with current clinical assays for CA125 (correlation coefficient of 0.89, 95% CI 0.83, 0.93). CA125 and HE4 were present at very low levels in healthy controls and benign cases, while higher levels were found in early stage cases, with highest levels found in the advanced stage cases. Overall, significant trends were observed for 38 of the 92 proteins (p < 0.001), many of which are novel candidate serum biomarkers for ovarian cancer. The area under the ROC curve (AUC) for CA125 was 0.98 and the AUC for HE4 was 0.85 when comparing early stage ovarian cancer versus healthy controls. In total, 23 proteins had an estimated AUC of 0.7 or greater. Using a naïve Bayes classifier that combined 12 proteins, we improved the sensitivity corresponding to 95% specificity from 93 to 95% when compared to CA125 alone. Although small, a 2% increase would have a significant effect on the number of women correctly identified when screening a large population.ConclusionsThese data demonstrate that the Proseek® technology can replicate the results established by conventional clinical assays for known biomarkers, identify new candidate biomarkers, and improve the sensitivity and specificity of CA125 alone. Additional studies using a larger cohort of patients will allow for validation of these biomarkers and lead to the development of a screening tool for detecting early stage ovarian cancer in the general population.Electronic supplementary materialThe online version of this article (doi:10.1186/s12014-017-9169-6) contains supplementary material, which is available to authorized users.

show abstract

“…The thioredoxin is a small protein playing pivotal roles in redox homeostasis and cell survival, and it is usually highly expressed in many cancers [ 105 ]. Indeed, in response to reactive oxygen species (ROS) associated with the tumors, thioredoxin and DJ-1 are upregulated to limit or reverse cell damages [ 106 , 107 ]. In our samples, we found two close isoforms of thioredoxin increased respectively of 3.7 and 2.5 folds in tumors.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

et al. 2017

View full text Add to dashboard Cite

The present investigation has been conducted on one hundred tissue fragments of breast cancer, collected and immediately cryopreserved following the surgical resection. The specimens were selected from patients with invasive ductal carcinoma of the breast, the most frequent and potentially aggressive type of mammary cancer, with the objective to increase the knowledge of breast cancer molecular markers potentially useful for clinical applications. The proteomic screening; by 2D-IPG and mass spectrometry; allowed us to identify two main classes of protein clusters: proteins expressed ubiquitously at high levels in all patients; and proteins expressed sporadically among the same patients. Within the group of ubiquitous proteins, glycolytic enzymes and proteins with anti-apoptotic activity were predominant. Among the sporadic ones, proteins involved in cell motility, molecular chaperones and proteins involved in the detoxification appeared prevalent. The data of the present study indicates that the primary tumor growth is reasonably supported by concurrent events: the inhibition of apoptosis and stimulation of cellular proliferation, and the increased expression of glycolytic enzymes with multiple functions. The second phase of the evolution of the tumor can be prematurely scheduled by the occasional presence of proteins involved in cell motility and in the defenses of the oxidative stress. We suggest that this approach on large-scale 2D-IPG proteomics of breast cancer is currently a valid tool that offers the opportunity to evaluate on the same assay the presence and recurrence of individual proteins, their isoforms and short forms, to be proposed as prognostic indicators and susceptibility to metastasis in patients operated on for invasive ductal carcinoma of the breast.

show abstract

Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients

Cited by 23 publications

References 46 publications

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

A multiplex platform for the identification of ovarian cancer biomarkers

Retrospective Proteomic Screening of 100 Breast Cancer Tissues

Contact Info

Product

Resources

About